Weekly Digest – September 2026 Weekly Digest – September 2026 21 September 2026: Telix and ITM join forces to create a radiopharmaceutical powerhouse Telix Pharmaceuticals announced a strategic agreement to merge with ITM Isotope Technologies Munich, creating a vertically integrated […]
Weekly Digest – September 2026 Weekly Digest – September 2026 22 September 2026: BoomRay enters exclusive global license agreement with Novartis for a novel radioligand therapy asset BoomRay announced an exclusive global license agreement with Novartis for a novel preclinical […]
Weekly Digest – September 2026 Weekly Digest – September 2026 16 September 2026: Enhertu and Datroway approved in Japan for two new 1L indications in metastatic Breast cancer Daiichi Sankyo announced that Enhertu and Datroway have been approved in Japan […]
Weekly Digest – September 2026 Weekly Digest – September 2026 16 September 2026: ELAHERE approved in Japan for patients with FRα-positive, platinum-resistant recurrent Ovarian cancer Takeda announced that ELAHERE has been approved in Japan for the treatment of folate receptor […]
Weekly Digest – September 2026 Weekly Digest – September 2026 15 September 2026: SYS6010 received NMPA BTD in China for actionable genomic alteration-negative non-squamous NSCLC CSPC Pharmaceutical Group announced that SYS6010 has received BTD from China’s NMPA for recurrent or […]
Weekly Digest – September 2026 Weekly Digest – September 2026 14 September 2026: Hengrui’s HER3 ADC, SHR-A2009 for injection, included in China’s Breakthrough Therapy list for NSCLC Hengrui Medicine announced that its HER3-directed ADC SHR-A2009 has been included in China’s […]
Weekly Digest – September 2026 Weekly Digest – September 2026 16 September 2026: Sino Biopharmaceutical announces NDA acceptance for TQB2102 in HER2-low Breast cancer in China Sino Biopharmaceutical has received China CDE acceptance of the NDA for TQB2102 in adults […]
Weekly Digest – September 2026 Weekly Digest – September 2026 16 September 2026: Escugen and Sovran expand collaboration to co-develop a novel bispecific ADC Escugen and Sovran Bio have entered into an agreement to co-develop a first-in-class, pan-tumor bispecific ADC, […]
Weekly Digest – September 2026 Weekly Digest – September 2026 08 September 2026: Adlai Nortye announced the first patient dosing in Australia and U.S. FDA IND clearance for AN4035 Adlai Nortye announced that the first patient has been dosed in […]
Weekly Digest – September 2026 Weekly Digest – September 2026 04 September 2026: Acepodia announces FDA clearance of IND application for ACE723, a novel dual-payload ADC Acepodia announced that the U.S. FDA has cleared the IND application for ACE723, a […]
